| Abstrakt: |
Researchers at Meizhou People's Hospital in China have conducted a study on Parkinson's Disease, focusing on the role of GSK-3(3 inhibitors in alleviating mitochondrial damage and neuronal cell loss. The study found that inhibiting GSK-3(3 activity promoted the nuclear translocation of TFEB, amplifying the autophagy-lysosomal pathway and improving motor function in mouse models of PD. This research suggests that targeting GSK-3(3 activity could be a potential therapeutic approach for delaying the progression of Parkinson's Disease. [Extracted from the article] |
